HPLC Analysis of Verapamil and Metabolites in Rat Plasma on Ascentis® Express C18 after Phospholipid Removal using HybridSPE®-Phospholipid
CONDITIONS
SPE well plate
HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample preparation
SPE (Solid Phase Extraction)
column
Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U)
sample/matrix
Rat plasma spiked with verapamil and metabolites at 10 ng/mL
mobile phase
[A] water; [B] acetonitrile, pH 2.55 adjust with formic acid (30:70, A:B)
flow rate
0.6 mL/min
column temp.
35 °C
detector
TOF/MS
injection
1 μL
sample addition
100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile
elution
apply vacuum
Description
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany